The term ‘baboon syndrome’(BS) was introduced 20 years ago to classify patie nts in whom a specific skin eruption resembling the red gluteal area of baboons occurred aftersy stemic exposure to contact allergens. The...The term ‘baboon syndrome’(BS) was introduced 20 years ago to classify patie nts in whom a specific skin eruption resembling the red gluteal area of baboons occurred aftersy stemic exposure to contact allergens. Thereafter, similar erupt ions have been reported after systemic exposure to beta-lactam antibiotics and other drugs. In addition to the presentation of 2 of our own cases, we have revi ewed and characterized the main clinical and histological aspects of published r eports of drug-related baboon syndrome (DRBS) and compared the primary clinical signs from such cases to those found in other distinct drug eruptions. Of appro ximately 100 published baboon syndrome cases, 50 were identified as drug-induce d. Of these, 8 were representatives of systemically induced contact dermatitis ( SCD), and 42 were examples of drug eruptions elicited by systemic administration of either oral or intravenous drugs. The main clinical findings included a shar ply defined symmetrical erythema of the gluteal area and in the flexural or inte rtriginousfolds without any systemic symptoms and signs. 14 of 42 cases were eli cited by amoxicillin, 30 of the 42 patients were male, and latency periods were between a few hours and a few days after exposure. DRBS is a rare, prognosticall y benign and often underdiagnosed drug eruption with distinct clinical features. The term baboon syndrome, however, does not reflect the complete range of sympt oms and signs and is ethically and culturally problematic. Moreover, baboon synd rome is historically often equated with a mercury-induced exanthem in patients with previous contact sensitization. Symmetrical drug-related intertriginous an d flexural exanthema, or SDRIFE, specifically refers to the distinctive clinical pattern of this drug eruption, and the following diagnostic criteria are propos ed:1)exposure to a systemically administered drug either at the first or repeat ed dose (excluding contact allergens); 2) sharply demarcated erythema of the glu teal/perianalareaand/orV-shaped erythema of the inguinal/perigenital area; 3) i nvolvement of at least one other intertriginous/flexural localization; 4) symmet ry of affected areas; and 5) absence of systemic symptoms and signs.展开更多
文摘The term ‘baboon syndrome’(BS) was introduced 20 years ago to classify patie nts in whom a specific skin eruption resembling the red gluteal area of baboons occurred aftersy stemic exposure to contact allergens. Thereafter, similar erupt ions have been reported after systemic exposure to beta-lactam antibiotics and other drugs. In addition to the presentation of 2 of our own cases, we have revi ewed and characterized the main clinical and histological aspects of published r eports of drug-related baboon syndrome (DRBS) and compared the primary clinical signs from such cases to those found in other distinct drug eruptions. Of appro ximately 100 published baboon syndrome cases, 50 were identified as drug-induce d. Of these, 8 were representatives of systemically induced contact dermatitis ( SCD), and 42 were examples of drug eruptions elicited by systemic administration of either oral or intravenous drugs. The main clinical findings included a shar ply defined symmetrical erythema of the gluteal area and in the flexural or inte rtriginousfolds without any systemic symptoms and signs. 14 of 42 cases were eli cited by amoxicillin, 30 of the 42 patients were male, and latency periods were between a few hours and a few days after exposure. DRBS is a rare, prognosticall y benign and often underdiagnosed drug eruption with distinct clinical features. The term baboon syndrome, however, does not reflect the complete range of sympt oms and signs and is ethically and culturally problematic. Moreover, baboon synd rome is historically often equated with a mercury-induced exanthem in patients with previous contact sensitization. Symmetrical drug-related intertriginous an d flexural exanthema, or SDRIFE, specifically refers to the distinctive clinical pattern of this drug eruption, and the following diagnostic criteria are propos ed:1)exposure to a systemically administered drug either at the first or repeat ed dose (excluding contact allergens); 2) sharply demarcated erythema of the glu teal/perianalareaand/orV-shaped erythema of the inguinal/perigenital area; 3) i nvolvement of at least one other intertriginous/flexural localization; 4) symmet ry of affected areas; and 5) absence of systemic symptoms and signs.
